Expanding platinum's potential

Researchers at Northern Illinois University and Ohio University have identified a new class of platinum complexes that exhibit anticancer activity without binding to DNA.1Although platinum-based cancer therapeutics are generally believed to work by binding DNA, this paper shows that these drugs may exert at least part of their effects through other mechanisms.

According to the researchers, the findings may lead to next-generation platinum-based cancer therapeutics with fewer side effects and less potential for drug resistance than marketed platinum drugs.

In a paper in the Proceedings of the National Academy of Sciences, the research group, led by Rathindra Bose, professor in the Department of Biomedical Sciences and the Department of Chemistry and Biochemistry at Ohio University, identified a class of platinum-phosphato complexes that did not

Read the full 1220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers